As neuropsychiatric drug development evolves, the field is  moving beyond traditional symptom scales toward richer,  multimodal endpoints capable of capturing true therapeutic  impact. This workshop explores emerging approaches: from  speech and digital behavioural biomarkers, to imaging derived circuit measures, physiological readouts, ecological momentary assessments and fluid biomarkers — that offer more objective, sensitive and patient centered ways to evaluate treatment response. Participants will examine how these endpoints can enhance early signal detection, refine patient stratification, reduce placebo interference, and support regulatory and clinical practice relevance. Through cross disciplinary discussion, the session will outline what high quality endpoint innovation looks like and what is needed to bring these tools into mainstream neuropsychiatric trials.

Workshop Objectives

• Identify the strengths, limitations and use cases of emerging digital, physiological, imaging and fluid based endpoints in neuropsychiatric clinical development
• Evaluate how novel endpoints can improve signal detection, reduce variability, and support precision based trial design across early and late clinical stages
• Define the evidence, validation steps and operational considerations required to make new endpoint technologies regulatory ready and scalable for widespread clinical adoption